CD8A and neoplasm: Similar outcomes have been shown in which IL-33, as a potent molecular adjuvant, can augment protective antiviral CD8+ T cell responses induced by a vaccine and boost DNA vaccine-induced protective anti-tumor T cell responses [29, 31].